
Medium-Term Business Plan SHIONOGI Transformation Strategy 2030 (STS2030) Revision

June 1, 2023 Shionogi & Co., Ltd.



Agenda

- 1. Reflections on STS Phase 1
- 2. Road to Realizing STS2030
- 3. STS Phase 2





1. Reflections on STS Phase 1



2030 Vision

Building Innovation Platforms to Shape the Future of Healthcare

SHIONOGI Group Vision (2030 Vision)

- What we want to achieve by 2030 -


Appearance after Vision is realized

- Continuously creating innovative products/services, with a well-established and rapidly-growing global business
 - Expansion of business model
 - Maintenance of high profit margins and growth after overcoming the patent cliff
- Continuing to offer solutions to health issues facing society
 - Freedom from the threat of infectious diseases, better QOL, extension of healthy lifespans, contribution to sustainable social security, and contribution to achieving SDGs
- Excellent business persons who never take a break from building their expertise and capabilities, leveraging their individual strengths and creating new value



Purpose of the STS Revision

- Significant progress toward achieving the 2030 Vision was made over the first three years of STS Phase 1
 - **⇒** The road to achieving the 2030 Vision has become clearer
- Initiating a new growth phase in STS Phase 2, raising financial targets





Reflections on STS Phase 1: Main Achievements

Expansion of products discovered internally

- Obtained domestic approval of ensitrelvir for COVID-19 treatment
- Strengthened overseas business
 - Growth of cefiderocol; GARDP*/CHAI*2 framework with MPP*3
- Achieved growth of the HIV franchise

Launch of products and services other than prescription drugs

- Filed application for domestic approval of COVID-19 vaccine
- Provided new products and services in the infectious disease and CNS areas
 - Wastewater surveillance service (AdvanSentinel), educational support (Yui Connection), brain activation by sound stimulus (kikippa), insomnia treatment app (SUSMED Med CBT-i®)

Governance enhancement

- Implemented new internal decision-making process
- Continued manager education

Achievement of major KPIs

(STS2030 target value in parenthesis)

		(S132030 target value in parentnesis)		
	KPI	FY2020	FY2021	FY2022
Growth	Revenue	297.2 B yen	335.1 B yen	426.7 B yen (400.0 B yen)
	Core operating profit* ⁴	94.0 Byen	110.6 B yen	158.5 B yen (120.0 B yen)
	Core operating Profit margin	31.6%	33.0%	37.1% (over 30%)
	Overseas sales ratio	16.2%	22.3%	16.9% (over 25%)
	Original pipeline ratio	71%	73%	61% (over 60%)
Shareholder return	EPS	365 yen	378 yen	619 yen (over 370 yen)
	DOE	4.1%	3.8%	3.9% (over 4%)
	ROE	13.9%	12.5%	17.8% (over 13%)



Reflections on STS Phase 1: Learnings and Points to Strengthen toward Transformation

Lessons from the COVID-19 experience

Renewed recognition of the threat of infectious diseases

The impact of COVID-19 on the world

Importance of the discovery of drugs for unmet needs

 Therapeutic and vaccine R&D efforts for COVID-19 were supported by many stakeholders

Lack of ability to deliver globally

• Lack of global sales and supply capabilities

Importance of business speed

The speed of COVID-19 drug discovery will become the standard

Recognition of the lack of capability to respond quickly to changes in the business environment

Points to strengthen toward transformation

Marketing capabilities -Ability to deliver globally-

- Develop a global marketing system; strengthen supply chains
- Develop sales routes for products and services other than prescription drugs

Pipeline -Investment in unmet needs-

- Invest in R&D, shifting resources flexibly to highest priorities/best opportunities
- Invest aggressively to acquire growth drivers

Strengthen company platform – Improve business speed; strengthen human resources-

- Making and implementing decisions: Improve speed in all aspects
- Revise/reinforce the necessary capabilities
 - Develop current human resources; hire outside personnel



2. Road to Realizing the 2030 Vision


- Three Pillars of STS2030 Revision -





STS2030 Revision: New Growth to Realize the 2030 Vision

- Continued growth of HIV franchise
- Growth centered around ensitrelyir (STS Phase 2: 2023-25)
- Growth toward realizing the 2030 Vision through aggressive investment (R&D, business investments) (-2030)





Current State and Future Outlook of the HIV Business


Continued growth will be achieved through the continuous introduction of products that meet patients' needs

Growth of Current Products Growth for Future HIV Products Strong growth of oral two drug regimens (Dovato, etc.) Growth of LA formulations and creation of new and smooth launch of long acting (LA) formulations products to meet future unmet needs in the HIV area In-house drug discovery research for combination (Cabenuva, Apretude) drugs for ultra-long-acting formulations Image diagram of changes in royalty income Peak sales growth due to Limitation of Renewed higher-than-expected revenues dolutegravir cliff due to growth from from oral two drug regimens increase in LA market LA progress and LA formulations share Revenue increase due to solid launch of oral Royalty income **New Scenario** two drug regimens and LA formulations **Old Scenario** (at the time of planning STS2030) 2022 2025 2028 2030 10 **SHIONOGI**

Actions and Outlook for COVID-19 treatments

Prediction and direction for COVID-19

- Our prediction: The epidemic continues as the virus evades immunity while continuing to mutate
- Our direction: Establish a position as the global standard COVID-19 drug based on clinical evidence



Actions for continuous growth of COVID-19 treatments

- Offer new evidence of ensitrelyir's value
 - High-risk outpatients, in-patients
 - Evidence of disease prevention, reduce risk of long COVID, etc.
- Provide ensitrelvir globally
 - Asia: File application for approval in East Asian countries and expand to ASEAN* countries
 - U.S., Europe: Approval and launch from FY2024
 - Other areas: Swift supply planned through partnering
- Discover even more convenient new therapeutic drugs such as S-892216



Expansion Centered Around New Products and New Business

Achieve growth by expanding existing asset and development portfolios and new business (vaccine business)

Growth of new products (prescription drugs)

Pipeline

To be launched by FY2025

- Resiniferatoxin (Pain associated with osteoarthritis) •
- Zatolmilast (Fragile X syndrome*)
- Daridorexant (Insomnia)
- Zuranolone (Depression)
- SUSMED Med CBT-i® * (Insomnia treatment app)

To be launched in or after FY2026

- Olorofim (Invasive aspergillosis)
- S-337395 (RSV infections)
- S-309309 (Obesity)
- S-151128 (Pain)
- Redasemtide (Ischemic stroke)
- S-531011 (Solid tumor)



- Cefiderocol
- Naldemedine and more

Growth of existing assets



in-licensing



Growth of the vaccine business

Expand globally from Asia and grow into a ¥100 billion business

Business development based on our strengths

OTC

CDMO**

Platform service business



Revise Major KPIs (key evaluation indicators)

- Revised revenue forecast for FY2030 (600.0 B yen ⇒ 800.0 B yen) due to business growth through expansion of global sales of ensitrelyir and HIV pipline/aggressive investment
- To promote aggressive strategic investment, adjusted one of the profit indicators from core operating profit to EBITDA*
- Incorporate non-financial indicators centered on the environment, human rights, and human capital*2

	STS Phase1	STS Phase2		STS Phase3
	FY2022	FY2023	FY2025	FY2030
Revenue	426.7 B yen	450.0 B yen	550.0 B yen	800.0 B yen
Overseas sales CAGR* ³	_		50% Starting from FY2022	15% Starting from FY2025
EBITDA	177.9 B yen	167.0 B yen	200.0 B yen	_



3. STS Phase2

Realizing our transformation

STS Phase1 ('20 -'22)

STS2030 Revision

Growth from transformation

STS Phase2 ('23 -'25)

STS Phase3 ('26 - '30)



Value Provided to Stakeholders

As a HaaS company, collaborate with stakeholders to contribute to solving healthcare-related social issues

Social issues to be addressed

Employees

Opportunities for growth

A safe workplace

Create value by solving healthcare social issues (Contribute to solving healthcare-related social issues)

- Protect people from the threat of infectious disease
- · Contribute to a healthy and prosperous life
- Contribute to sustainable social security, improve access to healthcare

Reduce negative impacts on customers and society

- Protect the environment
- Respect human rights
- Supply socially responsible products and services

Foundations that support the realization of a sustainable society and the growth of SHIONOGI

- · Securing human resources to support growth
- Strengthening supply chain management
- Adhere to compliance
- Strengthening governance



Customers

Those who require SHIONOGI's products and services

Products and services that meet unmet medical needs

-



Partners *

- Business models that enable partners to grow together with SHIONOGI
- A broad range of investments and partnerships not only for specific areas or of a particular size

Shareholders, investors

 Sustainable growth, profit returns



Overview of STS Phase2

Basic policy of the STS Phase2

Achieve global top-line growth and establishment of growth drivers through aggressive investment, especially in the infectious disease area

Create value by solving healthcare social issues

1

Protect people from the threat of infectious diseases

Materiality

Contribute to a healthy and prosperous life

(3)

Improve access to healthcare

Strengthen the management base and contribute to a sustainable society

4

Key Strategic Priorities
Global strategy, investment and
financial strategies

(5)

Transformation actions

6

Strengthening management and ESG Focus




Healthcare-related Social Issues Addressed by SHIONOGI

Work to address unmet needs to protect people from the threat of infectious diseases and "to contribute to a healthy and prosperous life

SHIONOGI's idea of unmet needs	 Healthcare issues and diseases that are expected to remain unsolved and increase over the next 10–20 years Issues and diseases for which the best solutions can be realized by combining SHIONOGI's strengths and external networks
Select focus needs	 The needs to be addressed are decided by management and addressed by R&D's high execution capability Break away from full in-house development to search for seeds and technologies and build networks worldwide
Concentrate resources	Implement bold resource allocations learned from COVID-19

Protect people from the threat of infectious diseases Diseases to be addressed: High-impact infectious diseases that threaten society Acute infectious diseases, incl. pandemic response Exacerbation suppression and aftereffect suppression Antimicrobial resistance (AMR) infections





Create value by solving social issues: ①Protect people from the threat of infectious diseases

Strategies for the Infectious Disease Business

Establish a business model for each area to achieve continuous growth Contribute to global health and stable supply

Build a sustainable business model

Acute infectious diseases (COVID-19, influenza, etc.)

Therapeutic drugs: Ensitrelvir, Xofluza

Achieve growth of ensitrelvir in the global market

Total care actions

 Achieve growth in the diagnosis, vaccine, and wastewater monitoring businesses

Antimicrobial resistance (AMR)

Work with society to create sustainable markets

- Roll out cefiderocol globally
- Introduce push and pull incentives
- Introduce rapid diagnosis that identifies antimicrobial-resistant bacteria and the mechanism of resistance

Build a stable business base by contributing to large numbers of patients

Infectious diseases requiring a long period of treatment (three major infectious diseases, etc.)

Cultivate new markets that address unmet needs

- Provide new solutions for HIV infection
- Develop a new drug (olorofim) against highly lethal fungal infections
- R&D of new treatments for infectious diseases with high unmet needs (tuberculosis, malaria, nontuberculous mycobacterial diseases)

Total care, including vaccines

Grow vaccines into the next earnings driver as a core business

- Launch COVID-19 and influenza vaccines
- Expand the business to Asia and across the world
- Establishment of new technologies that will be our strength (nasal, universal vaccines)

Strengthen diagnostic capabilities

• Provide simple diagnostic solutions (home diagnosis kits, etc.)



Create value by solving social issues: ①Protect people from the threat of infectious diseases

Global Rollout of Acute Infectious Disease Platforms

Offer total care globally that goes beyond medicines building a sustainable business model

Build a business portfolio that is not affected by epidemics

Establish a total care platform for acute infectious diseases


Build a sustainable business model

Establish a purchase model in collaboration with government, etc.

Build a disease portfolio

Make wide-ranging efforts to tackle key upper respiratory tract infections

- · COVID-19
- Influenza
- RSV and more





Create value by solving social issues: ①Protect people from the threat of infectious diseases

Actions and Outlook for the Vaccine Business

Aiming to grow the business into the next earnings driver, offering a steady business model less affected by patent cliffs

Up to FY2025 Up to FY2030 FY2030 onward Establish a track record as a vaccine manufacturer **Expansion into Asia** Launch COVID-19 vaccine Supply products from Japan to China Discover and launch influenza vaccine and ASEAN countries Establish a recombinant protein vaccine production **Global expansion** framework Cooperate with international organizations (e.g., WHO, Gavi*) Affordable provision to LMICs** Provide vaccines with added value to **Gaining competitive edge** the U.S. and European markets • Gain the ability to respond to the 100 days mission: Discover vaccines for SCARDA's core diseases • Establish new technologies by working backward from unmet needs - Develop nasal vaccines; develop a universal vaccine; consider new modalities



Create value by solving social issues: 2 Contribute to a healthy and prosperous life

Main Pipeline Products for Diseases with High Social/QOL Impact: To be launched in STS Phase2

Realize profit growth by delivering development pipeline products to patients/society

Resiniferatoxin (GRT7039)

- Indication: Pain associated with osteoarthritis
- A new painkiller option for patients with inadequate response to existing treatments

Zuranolone (S-812217)

- Indication: Depression, depressive state
- A new option for antidepressants, which have a low drug treatment response rate

Zatolmilast (BPN14770)

- Indication: Fragile X syndrome*
- Number of symptomatic patients: Around one in 10,000
- There are no approved medicines.

Digital app & healthcare

- SUSMED Med CBT-i[®]:Sleeping disorder treatment app
- SDT-001: Inattentive ADHD (pediatric)
- Kikippa: Brain activation by sound stimulus

Daridorexant

- Indication: Insomnia
- A new option for sleep medication, for which various issues have been reported (interrupted sleep, safety, etc.)

Symproic/Rizmoic

- Indication: Opioid-induced constipation
- A new treatment option for non-cancer OIC patients



Create value by solving social issues: 3 Improve access to healthcare

Actions to Improve Access to Healthcare

Delivering the necessary solutions (drugs and services) at the necessary time through various initiatives to improve access to medical care

Actions to protect people from the threat of infectious diseases

Improve access to LMICs

- Collaboration with GARDP/CHAI
- Collaboration with Medicines Patent Pool
- Listing on WHO Model List of Essential Medicines*

Promote and raise awareness of the proper use of infectious disease treatments

- In cooperation with and with support from ministries of health and experts in each country
- Holding educational seminars and practical classes for the general public

Actions to contribute to a healthy and prosperous life

Address problems that cannot be solved with medicine

- Supporting children with developmental disorders in communities, schools, and workplaces
- Provision of educational support system (Yui-EN)
- Supporting mother and child public health in Africa



 Elimination of communication barriers due to individual characteristics





Strengthen the management base and Contribute to a sustainable society

Building a Foundation for Realizing New Value Creation

Basic policy for building the management base

Create value by transforming our structure, changing the process that moves the structure, and developing human resources that can operate the process



that creates new value

5 Transformation actions

 Key actions to win in the global competition (Speed, corporate functions, DX platform) • Strengthening human capital management

Strengthening

management and

ESG Focus

• Growing in harmony with society while considering the environment and human rights





Strengthen the management base and Contribute to a sustainable society: 4 Key Strategic Priorites

Acceleration of Global Expansion

"Supply the best and necessary medicine globally" based on the SHIONOGI Group Heritage (the company policy of SHIONOGI)

Improve access to medical care, strengthen sales capabilities, and provide solutions (pharmaceuticals, etc.) globally







Strengthen the management base and Contribute to a sustainable society: <a>(4)Key Strategic Priorities

Strengthening of Global Sales Capabilities

Strengthening of global functions

Current state

- Establishment of a marketing system
 - Established the Integrated Disease Care
 Division in 2020
 - A marketing system focusing on Japan with a customer perspective and an emphasis on evidence
- Global rollout of cefiderocol
 - Expanding Access and Promoting Proper Use

Future actions

Establishment of a system for expanding global products, including ensitrelying

- Actions to improve access to healthcare
 - Global supervision of Market Access, Government Affairs, and Medical Affairs
- Establishment of a global sales system
- Four-pronged collaboration in marketing and supply chain
- Strengthening Commercial Human Resources: Developing Frameworks for Global Recruitment

Regional policies

Japan

Drive the market as the leading company in the area of infectious diseases

U.S.

Establish the optimal sales organization for the sale of ensitrelyir

Europe

Efficiently expand country presence by selecting a business model for each country without limiting to inhouse sales

Asia

- China: Switch to a new drug model; achieve new drug growth
- ASEAN: Enter the market as soon as possible



Strengthen the management base and Contribute to a sustainable society: 4 Key Strategic Priorities

Building a Foundation for Realizing

Improve the resilience of increasingly important supply chain management to strengthen global supply capabilities

Lessons from environmental changes

- The importance of the ability to swiftly expand production and supply capacities to contribute to tackling the pandemic
- The necessity of procurement and production systems that do not depend on a specific region
- The importance of supply chain network management

Past actions (STS Phase 1)

- Expansion of supply destination countries: Multiplexing of global supply and production of cefiderocol
- Expansion of production capacity: Establishment of a production system for the global supply of ensitrelyir
- Timely supply-demand adjustments: Establishment of production and supply systems tailored to the application and approval status in each country

Points to strengthen in global supply chains

Improvement of global supply speed and capability

 Establish a global network with preferred CMOs and suppliers

Sustainable procurement that takes into consideration the environment, human rights, and occupational health and safety

 Strengthen the ESG management system in accordance with international norms and standards

Establishment of a sustainable distribution system for acute infectious disease drugs

- Effective use of healthcare resources (reduce waste)
- Stable domestic supply of antibacterial drugs

Pursue quality and efficiency by promoting DX

 Efforts to optimize production plans and improve quality using Al and digital technology



Strengthen the management base and Contribute to a sustainable society: 4 Key Strategic Priorities

Investment and Financial Strategies

Reflections

R&D investments

 Achieved results with ensitrelvir through investments and risk-taking beyond the investment limit

Business investments (in-licensing, M&A, etc.)

• Fell significantly short of the ¥500 billion target

Future direction

- Based on our robust financial base, invest aggressively for regional expansion leveraging our strength in infectious diseases to establishing new earnings drivers
- Continue our policy of enabling shareholders to actually feel SHIONOGI's growth



 Robust financial base leveraging cash on hand and good credit standing

Investment strategy

R&D:

¥300 billion R&D expenditure planned over three years

Business investment:

Make aggressive investments, including M&A and in-licensing.

Determine the value of projects and make investments worth the value without being limited by the investment size

Financial strategy

Financial KPIs (FY2025)

• DDOE: 4%

EPS: ¥600 over

• ROE: 14% over

 The basic policy is to increase dividends for 14 consecutive fiscal years

 Conduct flexible share buybacks according to the state of investments and the market



Strengthen the management base and Contribute to a sustainable society: ⑤Transformation actions

Action to Increase Global Competitiveness

Achieve operational transformation/value creation globally, leveraging our experience from COVID-19 drug discovery

Outcomes of STS Phase 1 improved speed, development of operational infrastructure

- New business processes learned from COVID-19 drug discovery
- Substantial revision the approval system
- Drastic business process improvement:
 Establishment of joint venture with
 Accenture for indirect operations
- Establishment of IT infrastructure: Global response to security and personal information protection

Strengthen global corporate functions

- Redefining corporate functions in alignment with the globalization of business.
- Strengthening global strategy, global governance, and stakeholder engagement

Realization of Dx transformation

- Business model & operation reforms:
 Improvement of drug discovery efficiency using AI, market inventory forecast, etc.
- Creating value by promoting data utilization: Creating value by developing SaMD* and disease detection algorithms



Strengthen the management base and Contribute to a sustainable society: 6 Strengthening management and ESG

Strengthen Human Capital to Achieve the 2030 Vision

Acquire new Capabilities/Promote in-house integration and execute growth scenarios

Build on our existing strengths (business execution capabilities, expertise) to acquire and develop new strengths

Evaluate the progress of initiatives using KPIs and strengthen dialogue with stakeholders (Major KPIs: short-term – succession plan execution status, self-investment support utilization rate, etc., medium- to long-term – progress in talent management, etc.)

Points to strengthen regarding human capital

Human resource power (individual power)

Transform the human resources portfolio to achieve STS2030

<Strengthen hiring of outside personnel >

 Enhance competitiveness of the compensation system

<Competence-oriented personnel recruitment >

 Ensure appropriate compensation by regrading all employees following the introduction of a new personnel system

< Promoting reskilling >

 A self-investment support system that encourages employees to think about their own careers and promotes their growth

D&I

Ensure diverse values and integrate diverse human resources

<Leverage diversity to generate added value >

- Carry out workstyle reforms to empower human resources of various attributes
- Activate D&I activities

Engagement

Practice and disseminate management philosophy

<Enhance branding activities >

- Activate communication through brand logo revision
- <Encourage employees to take on challenges >
- Hold events to welcome and praise employees taking on challenges





Strengthen the management base and Contribute to a sustainable society: 6 Strengthening management and ESG

Addressing material issues impacting customers and society

Aiming to achieve both growth as a company and contribution to a sustainable society by strengthening our response to material sustainability issues through dialogue with stakeholders

Environ ment

Implement the 2030 CO2 reduction plan to become carbon neutral

[Medium-term target]

Scope1·2: FY2030: 46.2% reduction (compared to FY2019) Scope3: FY2030: Category 1 20% reduction (compared to FY2019)

Society

Reinforcement of Consideration for Human Rights in Our Company and Partners [Medium-term target]

- Continuous implementation of human rights due diligence
- Risk assessment of important partners, on-site audits

External evaluation results

 Became the first pharmaceutical company to be certified as an "Eco-First Company"



- FTSE: 3.6, MSCI: AA, DJSI: 63
- CDP Climate, Water Security:
 Double A List





Summary: Overview of STS Phase 2 ('23 -'25)

Build on the results of Phase 1 to achieve global growth

- Leverage business capability that was improved in all aspects during the COVID-19 pandemic
- Achieve significant global growth over three years, centered around ensitrelyir

A paradigm shift of the HIV franchise

- The market environment changed drastically, including the growth of longacting formulations
- Progress R&D for even more significant growth in the medium to long term

Acquire growth drivers

- Enhance the pipeline through aggressive investment leveraging a robust financial base
- Concentrate investment in high-need, high value pipeline assets; shift resources flexibly, with approaches cultivated through COVID drug discovery

Strengthen the management base

- Transform human resources and the organization
- Promote ESG management: Achieve growth in harmony with society



SHIONOGI Group Heritage

SHIONOGI strives constantly to supply the best possible medicine (healthcare solutions) to protect the health and wellbeing of the patients we serve.

The three years of STS Phase 2 will be a period of global realization of the SHIONOGI Group Heritage (basic policy).

By creating social value, we will continue to grow sustainably together with our stakeholders.



Appendix



Direction for the New SHIONOGI

Delivering value by providing healthcare as a service

(Healthcare as a Service : HaaS)

 Generate new value and solve problems faced by patients and society through collaborative invention with a diverse range of partners

Augment the strengths we have acquired through the discovery and development of "medicinal drugs," and leverage those strengths

An era in which patients select medical care from a wide variety of solutions/information

More sophisticated and compartmentalized medical and social needs

Need to ensure sustainability for social security

Acceleration of technological innovation and data utilization

Current SHIONOGI

Providing medicinal drugs as a drug-discoveryoriented pharmaceutical company

Transform

♦ Direction for the New SHIONOGI

Continuously enhance our "strengths" as a drugdiscovery-oriented pharma company, become the premier partner for other companies/industries for its unique strengths, build new platforms in the healthcare arena, and provide new value to society as a healthcare provider



Pipeline: Infectious Disease

as of June 1, 2023

Phase 2 Phase 3 Preclinical Phase 1 Submission F901318 S-217622* S-217622*2 S-872600 S-337395 [Olorofim] [Ensitrelvir] [Ensitrelvir] Influenza nasal vaccine **RSV** infections COVID-19 treatment COVID-19 treatment **Invasive Aspergillosis** S-268019*3 S-217622 **Cefiderocol** S-875670 S-892216 COVID-19 Aerobic Gram-negative [Ensitrelvir] COVID-19 nasal vaccine COVID-19 treatment bacterial infection (Pediatric) COVID-19 prevention Prophylactic vaccine S-268019 S-217622 S-540956 Cefiderocol*4 COVID-19 [Ensitrelvir] Nucleic acid adjuvant Various infectious diseases Prophylactic vaccine COVID-19 treatment(Ages 5-11) S-554110 S-268019 **Xofluza** Nontuberculous Influenza virus infection COVID-19 mycobacterial infection (Granules, < 20kg) (Ages 5-19)



Out license

S-365598 HIV infection

S-555739 [Asapiprant]

Treatment by suppressing aggravation of COVID-19

Xofluza

Influenza virus infection (Pediatric, < 1 year old)

Xofluza

Influenza virus infection (Transmission)

Xofluza(US)

Influenza virus infection (Pediatric, < 1year old)



Pipeline: QOL Diseases with High Social Impact

S-723595

NASH

as of June 1, 2023

Phase 1 Preclinical Phase 2 Phase 3 Submission S-005151* S-812217 S-309309 S-540956 S-151128 [Redasemtide] [Zuranolone] Nucleic acid adjuvant Chronic pain Obesity Acute ischemic stroke Depression S-005151 **GRT7039** S-531011*2 S-109802 S-588210 [Redasemtide] [Resiniferatoxin] Post-stroke spasticity Solid tumor Solid tumor Pain associated with knee Epidermolysis bullosa osteoarthritis **BPN14770 BPN14770** BPN14770*5 [Zatolmilast] [Zatolmilast] [Zatolmilast] Alzheimer's disease Alzheimer's disease Fragile X Syndrome Rizmoic*3 **SDT-001** S-588410 Opioid-induced Inattentive ADHD Bladder cancer constipation(pediatric) (pediatric) ADR-001*4 S-588410 S-588410 Decompensated liver Bladder cancer Esophageal cancer cirrhosis S-222611 S-488210 Global development SR-0379 Head and neck squamous [Epertinib] Cutaneous ulcer **Out license** cell carcinoma Malignant tumor S-0373 [Rovatirelin]



Spinocerebellar

Degeneration